Intravenous ceftriaxone 2 g o.d. was substituted for the trimethoprim-sulfamethoxazole. A review after 6 months of ceftriaxone demonstrated complete resolution of the ocular changes (images not shown), and on the basis of this finding, the patient was converted back to oral trimethoprim-sulfamethoxazole 160/800 mg b.d. Six months later, he again presented with visual blurring and evidence of macular edema and chorioretinitis (images not shown), necessitating a further 5-month course of intravenous ceftriaxone. He remains on oral trimethoprim-sulfamethoxazole and has had no further clinical problems to this date. His C-reactive protein remains in the normal range. Lymph node samples from the lymphoma staging laparotomy performed 19 years previously were obtained and were also tested by PCR for the presence of T. whippelii DNA (Maibach, Switzerland). The result was negative.
At present, there is little evidence to guide the treatment of Whipple disease. Current recommendations are based on the observation in retrospective cohorts that treatment with tetracycline was associated with a higher rate of relapse, particularly cerebral, compared with cotrimoxazole.5,6 This has been attributed to tetracycline failing to cross the blood-brain barrier. Current recommendations are an initial 2 weeks of intravenous ceftriaxone, particularly if there is evidence of CNS involvement, followed by oral trimethoprim-sulfamethoxazole 160/800 mg b.d. for at least a year.7 The first randomized controlled trial addressing the issues of choice and duration of antibiotic therapy and the use of gamma interferon as an immunomodulatory agent is currently in progress.8
Our patient had a large cell non-Hodgkin lymphoma at the age of 28 years, 19 years before he was diagnosed with Whipple disease. An association has been reported between lymphoma and Whipple disease, lymphomagenesis possibly occurring as a result of chronic antigenic stimulation. Lymphomagenesis occurs as a result of a monoclonal B-cell population gradually accumulating genetic mutations with decreasing response to external regulation.9 A number of case reports describe possible steps along that pathway in patients with Whipple disease. In one case, a patient with Whipple disease and massive lymphadenopathy was shown to have a clonal population of B cells with a BCL2-mbr rearrangement, a recognized step in lymphomagenesis.10 The lymphadenopathy and the clonal B-cell population disappeared after treatment of the Whipple disease, suggesting that monoclonal B-cell proliferation may have been antigenically driven by T.whippelii. In a similar case of Whipple disease with massive lymphadenopathy, a κ-restricted B-cell clone was isolated from blood, bone marrow, and spleen without evidence of lymphoma.11 The lymphadenopathy regressed after antibiotic treatment of the Whipple disease, but the monoclonal population persisted. Last, 2 cases of lymphoma occurring after treatment of Whipple disease have been described.12,13 This situation can be compared with other oligoclonal or monoclonal "smouldering" conditions associated with autoimmune diseases, hepatitis C, and Helicobacter pylori infection, which are at risk of evolution to lymphoma.14,15 Interestingly, antibiotic treatment of H. pylori infection has been associated with regression of primary low-grade B-cell gastric mucosa-associated lymphoid tissue lymphoma.16,17
A wide range of immune deficiencies has been reported in the context of Whipple disease, in particular reduced CD4 to CD8 T-cell ratio, impaired phagocytosis capacity of macrophages, and decreased Il-12 secretion leading to decreased gamma interferon production from Th1 T cells.18 It is unclear to what extent these changes precede the development of Whipple disease and to what extent they are a consequence of infection with T. whippelii, and indeed, some changes have been reported to disappear after successful treatment.19
It is interesting to speculate on the factors that lead to this particular patient becoming infected with T. whippelii. Could he have been infected before the development of lymphoma, lymphomagenesis resulting from the chronic antigenic stimulation of infection? We were unable to demonstrate T. whippelii DNA on samples from the original staging laparotomy for lymphoma, but it should be noted that PCR for T. whippelii is less sensitive when performed on paraffin-embedded tissues compared with fresh tissue (R. Maibach, personal communication). It seems much more plausible, however, that he became infected more recently, perhaps related to an increased susceptibility to infection after the splenectomy and the development of type 2 diabetes.
1. Maibach RC, Altwegg M. Cloning and sequencing an unknown gene of Tropheryma whipplei
and development of two LightCycler PCR assays. Diagn Microbiol Infect Dis
2. Dutly F, Altwegg M. Whipple's disease and "Tropheryma whippelii
." Clin Microbiol Rev
3. Fleming JL, Wiesner RH, Shorter RG. Whipple's disease: clinical, biochemical, and histopathologic features and assessment of treatment in 29 patients. Mayo Clin Proc
4. von Herbay A, Ditton HJ, Schuhmacher F, et al. Whipple's disease: staging and monitoring by cytology and polymerase chain reaction analysis of cerebrospinal fluid. Gastroenterology
5. Feurle GE, Marth T. An evaluation of antimicrobial treatment for Whipple's disease. Tetracycline versus trimethoprim-sulfamethoxazole. Dig Dis Sci
6. Misbah SA, Mapstone NP. Whipple's disease revisited. J Clin Pathol
7. Gilbert DN, Moellering RC Jr, Eliopoulos GM, et al. The Sanford Guide to Antimicrobial Therapy. Sperryville, VA: Sanford; 2006.
9. Dolcetti R, Boiocchi M. Cellular and molecular bases of B-cell clonal expansions. Clin Exp Rheumatol
. 1996;14 Suppl 14:S3-S13.
10. Fest T, Pron B, Lefranc MP, et al. Detection of a clonal BCL2 gene rearrangement in tissues from a patient with Whipple disease. Ann Intern Med
11. Wang S, Ernst LM, Smith BR, et al. Systemic Tropheryma whippleii
infection associated with monoclonal B-cell proliferation: a Helicobacter pylori
-type pathogenesis? Arch Pathol Lab Med
12. Gruner U, Goesch P, Donner A, et al. Whipple disease and non-Hodgkin lymphoma. Z Gastroenterol
13. Gillen CD, Coddington R, Monteith PG, et al. Extraintestinal lymphoma in association with Whipple's disease. Gut
14. Mariette X. Lymphomas complicating Sjogren's syndrome and hepatitis C virus infection may share a common pathogenesis: chronic stimulation of rheumatoid factor B cells. Ann Rheum Dis
15. Dammacco F, Sansonno D, Piccoli C, et al. The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. Semin Liver Dis
16. Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori
17. Morgner A, Bayerdorffer E, Neubauer A, et al. Gastric MALT lymphoma and its relationship to Helicobacter pylori
infection: management and pathogenesis of the disease. Microsc Res Tech
18. Marth T, Roux M, von Herbay A, et al. Persistent reduction of complement receptor 3 alpha-chain expressing mononuclear blood cells and transient inhibitory serum factors in Whipple's disease. Clin Immunol Immunopathol
19. Dobbins WO III. HLA antigens in Whipple's disease. Arthritis Rheum